IQVIA Raises 2026 Forecast Following Record Q2 Bookings

IQVIA Holdings Inc. raised its full-year 2026 sales guidance to a range between $17.275 billion and $17.475 billion following strong second-quarter financial results. The company reported total revenue of $4.368 billion, representing an 8.7% year-over-year increase, and adjusted diluted earnings per share of $3.15.

Performance was primarily driven by the Research & Development Solutions division, which achieved record net new bookings of $3.15 billion. This growth contributed to a total contracted backlog of $34.2 billion. The company also projected adjusted EBITDA for the year to be between $4.0 billion and $4.05 billion.

These results exceed previous internal guidance and analyst estimates. The company attributes the growth to a broader recovery in clinical research and increased biopharma investment in complex biologic pipelines and AI-powered trials.